Trillium Therapeutics

$20.30
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.28 (+13.11%) Today

+$0.63 (+3.20%) As of 10:25 AM UTC after-hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, and ETFs commission-free!

About TRIL

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. The listed name for TRIL is Trillium Therapeutics Inc. Common Shares.

CEO

Jan Skvarka

Employees

Headquarters

Mississauga, Ontario

Founded

2004

Market Cap

1.74B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

2.00M

High Today

$20.14

Low Today

$17.91

Open Price

$18.10

Volume

1.99M

52 Week High

$20.14

52 Week Low

$0.29

Collections

Analyst Ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

TRIL Earnings

-$1.07

-$0.71

-$0.36

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Estimated

— per share

Actual

-$0.55 per share